Updated:
Clario
Clario traces its origins to a clinical trial technology business that has operated for over 50 years (per the firm).
Clario
Clario traces its origins to a clinical trial technology business that has operated for over 50 years (per the firm). It now operates as a business unit within Thermo Fisher Scientific, which acquired the firm (the legacy clinical services arm previously known as ERT and Bioclinica) to strengthen its clinical research offerings. The firm's strategy centers on providing an integrated endpoint technology platform that covers cardiac safety (ECG, blood pressure, arrhythmia), eCOA (electronic clinical outcome assessments), medical imaging (CT, MRI, endoscopy, with an AI redaction tool), precision motion (wearable sensors), and respiratory testing (spirometry, cough assessment). Clario targets clinical trials across Phase I through Phase III, serving sponsors in biotech, pharma, and CRO segments. The platform has supported 700+ FDA and EMA drug approvals since 2015 (per the firm). Clario does not disclose AUM, deployment figures, or team size. However, the firm states it has supported over 30,000 clinical trial opportunities and operates in 100+ countries. An additional office is located in Montréal, QC, Canada. There is no public record of philanthropic or adjacent vehicles. The firm's structural differentiator lies in its breadth: it claims the broadest endpoint technology platform in the industry, combining multiple modalities under one roof. Being part of Thermo Fisher Scientific gives it scale advantages in infrastructure, procurement, and regulatory compliance that standalone CROs may lack.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Philadelphia
Corporate office
Philadelphia, PA, United States
Additional offices
Montréal, QC, Canada
Sector focus
Frequently asked questions
Who owns Clario?
Clario is a business unit of Thermo Fisher Scientific, a publicly traded life sciences company. The firm presents itself as 'part of Thermo Fisher Scientific' on its website and corporate materials.
What endpoint technologies does Clario offer?
Clario offers a broad endpoint technology platform that includes cardiac safety (ECG, blood pressure monitoring, arrhythmia analysis), electronic clinical outcome assessments (eCOA), medical imaging (CT, MRI, endoscopy with AI redaction), precision motion (wearable sensors for mobility endpoints), and respiratory solutions (spirometry, cough and lung sound analysis).
How does Clario generate deal flow or client relationships?
Clario does not raise capital from external LPs for investment; it is a business-to-business clinical services provider. Client relationships typically come through pharmaceutical companies, biotechs, and contract research organizations that require endpoint data collection for clinical trials.
What therapeutic areas does Clario focus on?
Clario covers cardiovascular and metabolic, dermatology, diabetes and obesity, gastroenterology, hepatology, infectious diseases, musculoskeletal, neuroscience (dementias, headache disorders, movement disorders, multiple sclerosis, pain, psychiatric), oncology, ophthalmology, and respiratory.
Does Clario use artificial intelligence in its services?
Yes, Clario deploys AI in several areas, notably its Image Redact AI tool that automatically redacts patient identifiers from medical images, videos, and PDFs. The firm also uses AI in respiratory data interpretation and across its imaging platform.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: